Blurbs

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sarepta Therapeutics (SRPT) and Karuna Therapeutics (KRTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGNResearch Report), Sarepta Therapeutics (SRPTResearch Report) and Karuna Therapeutics (KRTXResearch Report).

Amgen (AMGN)

In a report released today, Steve Chesney from Atlantic Equities maintained a Sell rating on Amgen, with a price target of $182.00. The company’s shares closed last Monday at $247.29.

According to TipRanks.com, Chesney is a 2-star analyst with an average return of 1.2% and a 42.9% success rate. Chesney covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Johnson & Johnson, and Merck & Company.

The word on The Street in general, suggests a Hold analyst consensus rating for Amgen with a $241.92 average price target, a -1.3% downside from current levels. In a report issued on July 28, Robert W. Baird also maintained a Sell rating on the stock with a $185.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics, with a price target of $182.00. The company’s shares closed last Monday at $111.47, close to its 52-week high of $111.90.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 3.1% and a 48.4% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Enanta Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $131.00, representing a 23.6% upside. In a report issued on July 25, SVB Securities also maintained a Buy rating on the stock with a $126.00 price target.

Karuna Therapeutics (KRTX)

SVB Securities analyst Marc Goodman maintained a Buy rating on Karuna Therapeutics today and set a price target of $270.00. The company’s shares closed last Monday at $241.19, close to its 52-week high of $245.00.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 2.5% and a 47.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Karuna Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $225.58, representing a 2.1% upside. In a report released yesterday, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed